Ivosidenib

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策 ☝ ☝ 点击查看峰会活动议程 ☝ ☝  前言 近年来，我国虽已经基本实现全民覆盖，但基本医保的定位是广覆盖、保基本，讲究的是“一视同仁”，不可能“大包大揽” ，因而加强商业健康险作为基本医疗保险的补充成为一条可行且必要的途径。此外， 随着老龄化的加剧，老年人群几乎被各种商业保险拒之门外。在此背景下，惠民保本着广泛保障、普惠于民的理念应运而生。 2025年7月国家医保局首次提出建立商保创新药目录并开始逐步实施，惠民保作为近几年热门的商保产品之一，第一版商保创新药目录出台后或将会优先落地在惠民保产品上，再逐步推广至其他商保。对于创新药企业而言，又多了获得市场的机遇。 什么是惠民保? 惠民保又称城市定制型商业医疗保险，一般是由各地地方政府牵头，由商业保险承保的一款“普惠型”的商业医疗保险。惠民保作为一款面向基本医保参保人员的政策性保险，是在大病费用负担重的情况下应运而生的，目的是为了减轻投保人员大病大额医疗费用的开销。 惠民保是如何发展的？ 2015年，深圳医保局联合平安保险最先推出了“深圳重特大疾病补充医疗保险”，标志着“惠民保”产品雏形的出现。随后2018到2019年间，南京、广州、珠海、佛山等城市先后出现相似的产品，但都没有在国内引起大的水花。直到2020年3月《关于深化医疗保障制度改革的意见》政策发出，指出“到2030年，全面建成以基本医疗保险为主体，医疗救助为托底，补充医疗保险、商业健康保险、慈善捐赠、医疗救助共同发展的医疗保障制度体系。”此后，惠民保开始在全国范围内迅速走红。参保人数在不到一年的时间迅速突破4000万，2020年更是被业内称为“惠民保元年”；此后惠民保进入高速发展阶段。2024年国家和地方发布政策加强惠民保产品监管，惠民保发展延缓，逐步转向专业化、规范化发展。 在惠民保漫长的发展过程中，国家层面发布的相关重要政策如下： ❖2020年3月，国务院发布的《关于深化医疗保障制度改革的意见》，提出促进多层次医疗保障体系发展，成为惠民保市场爆发的重要契机。 ❖2021年5月，中国银保监印发了《中国银保监会办公厅关于规范保险公司城市定制型商业保险业务的通知》，鼓励政府部门参与惠民保项目，进一步规范惠民保发展。 ❖2022年5月，国家发布《国务院办公厅印发深化医药卫生体制改革2022年重点工作任务的通知》提出“探索推进医保信息平台按规定与商业健康保险信息平台信息共享”；同月，中国银保监发布《中国银保监会关于印发保险业标准化“十四五”规划的通知》提出：“推动制定商业保险与医疗、社保部门的数据共享和交换标准，促进普惠型保险的健康发展。”积极推进医保数据和商保数据共享。 ❖2024年12月，国家医保局召开全国医疗保障会议指出要健全多层次医疗保障，在完善基本医保三重保障制度的前提下，积极推动商业保险如惠民保创新发展。 ❖2025年7月，国家金融监督管理总局向保险行业正式下发《关于推动城市商业医疗险高质量发展的通知》，从保险定位、产品保障、产品定价、监督管理等方面积极推动产品实现商业化可持续发展。 惠民保发展规模如何？ 截至2025年7月31日，惠民保（含已结束产品）现已覆盖全国30省（包括4个直辖市和3个自治区），184个地级市（不含上线全省通用的地级市）；有310款产品（不同年份和不同版本的视为同一产品） 。此外还有面向全国20款惠民保产品上线，共计330款产品。目前仅有西藏暂未发布任何惠民保相关产品，各省具体惠民保产品数量如下： 截至7月31日，全国已有184个地级市上线了惠民保（包括已结束的产品）。多数省份对外发布省级指导产品；只有新疆、西藏、云南、浙江4个省（自治区）从未发布全省通用版，其中浙江省虽然没有省级惠民保产品，但省政府发布政策统一指导下面地级市自行发布产品，“浙里惠民保”系列产品也几乎覆盖所有地级市。 已上线惠民保产品的省份，不仅在惠民保数量上有差距，在开通惠民保的地级市数量上差距也很大。各省已上线惠民保数据如下图： 广东省21个地级城市全面上线惠民保相关产品，有些地级市还不止1款，上线地级市是所有省份中最高的一个。除广东外，山东以及广西下辖的地级市也均都上线了惠民保产品。山东省在推动惠民保发展上尤为积极，全省16个地级市在不到两年的时间纷纷发布惠民保产品；而广西则在2022年“异军突起”开创了“广西模式”，在2022年完成0的突破并实现地级市全面覆盖。截至7月底，已有3个省（自治区）实现了地级市均有惠民保的目标。 惠民保为什么能够大火？ 目前市面上商业保险众多，但发展迅速的热门产品当属惠民保，其主要爆火原因可能有以下几方面： （一）有需求 ✦基本医疗保险和大病保险以及普通的商业健康险作为群众的保障，但对于“带病体”来说远远不够。国家近几年在鼓励创新药进医保，但由于医保基金的局限性，市面上很多的高额费用药品没办法顾及到。 ✦普通商业健康险又限制参保人健康状况，面对价格昂贵的自费药，患者急需一款像“惠民保”这类的产品来减轻经济负担。 （二）有市场 ✦在需求不断增加的情况下，市场也应运而生.患者有意愿为产品买单，就会有企业投入开发市场。 （三）有支持 ✦基于目前我国基本医疗保险“广覆盖、保基本”的现状，加强商业健康险作为基本医疗保险的补充成为一条可行且必要的途径。当时市面上出现一款能够满足更多群体投保的产品，国家政策和政府部门也愿意支持。 ✦有了政策和政府的加持，也将有更多的保险公司、第三方机构、药企等加入其中，从而促进惠民保的快速发展。 惠民保特药保障怎样？ 特药保障是“惠民保”产品的重要卖点，也是对于目录外高额医药费用保障的重要补充。截至7月31日，共有185款惠民保产品在售/在执行（不含全国版）；其中有165款产品包含特药保障。在165款有特药保障的惠民保中按照药品纳入产品的数量统计出截至7月31日排名前30的特药名称，如下图： 排名前十名的特药纳入的惠民保数量全都不低于115款，占目前未结束总产品数量的68%左右；是惠民保特药的热门药品。对比本次国家医保局公示的通过形式审查的商保创新药目录来看，惠民保TOP30中的药品除去德曲妥珠单抗、西达本胺、维泊妥珠单抗以及卡度尼利单抗4种医保目录内药品以及肿瘤电场治疗仪外，只有9种药品没有在形式初审的公示名单中，分别为：度伐利尤单抗、塞普替尼、雷莫西尤单抗、帕博利珠单抗、佩米替尼、盐酸美法仑、艾伏尼布、派安普利单抗和格菲妥珠单抗。这9种药品种又有超过半数在基本医保目录形式初审公示名单中；仅有度伐利尤单抗、雷莫西尤单抗、帕博利珠单抗和佩米替尼两个名单都不在。 惠民保未来前景怎样？ 惠民保虽在前几年发展势头迅猛，但这两年略显后劲不足；不少产品都面临续保率降低的现象，也有部分产品在第一轮保障期结束后就销声匿迹。目前来说，惠民保面临最大的问题就是如何在保证不亏损的情况下提高参保人续保意愿。针对这种局面，国家和地方政府都在努力推动惠民保可持续发展。不少地方政府都发文支持本地惠民保产品发展，并且逐步规范产品专业性。2025年7月底，国家金融监管局发文对惠民保提出一系列建议，积极推动惠民保商业化可持续发展。此外国家今年建立商保创新药目录，并已经开始第一轮尝试；8月12日国家医保局公示通过形式初审的商保创新药目录名单，共有121个药品。对比基本药品目录名单数量少了很多，但首次尝试，不少药企都还处于观望状态。商保创新药目录旨在为商保选择药品提供指导意见，第一版目录出台后或将优先落地在国家和地方更青睐的惠民保产品上，再逐步向其他商保推广。商保创新药目录目前虽还在试水阶段，但从医保局今年的政策动态来看，未来也将和基本医保目录一样进入常态化调整。惠民保的未来还是比较明朗。 国家和地方在大方向上对惠民保保持支持态度；而惠民保健康发展对患者、药企、国家都有利可言。尤其对药企来说，更是多了一种获得市场的机会。       (来源：易联招采网） 药闻康策 新媒体矩阵微信公众号 点击下方  一键关注 【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。 欢迎转发分享、点赞、点在看

Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Generated $59.6 million of net income in the second quarter of 2025 Updated 2025 Outlook: Total revenue of approximately $270 to $280 million, which includes net product sales of $210 to $220 million Total revenue and net income are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress. "Our strategic and disciplined approach to building our business has generated another strong quarter for the company. In the second quarter, we grew net product sales by 76% year-over-year, generated $59.6 million in net income and increased our cash balance to $108.4 million. This strong performance has enabled us to raise our 2025 financial guidance," said Raul Rodriguez, Rigel's president and CEO. "We're also excited by the continued advancement of our hematology and oncology development pipeline. In July, we completed enrollment in the dose escalation part of our ongoing Phase 1b study evaluating R289 in patients with relapsed or refractory lower-risk MDS. Later this year, we plan to share updated data from that study and initiate the dose expansion part of the study." Second Quarter 2025 Business Update Commercial Net product sales were $58.9 million, an increase of 76% from the same period of 2024. Rigel's partner Kissei Pharmaceutical Co., Ltd. (Kissei) announced that its licensing partner, JW Pharmaceutical Corporation, commercially launched TAVALISSE in South Korea in early July. Corporate In April, Rigel notified Eli Lilly and Company (Lilly) that it would not exercise its opt-in right related to the development and commercialization of ocadusertib (previously R552) for the treatment of non-central nervous system (CNS) diseases. As a result of the notification, Rigel recognized $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability in the second quarter. Per the agreement with Lilly, Rigel will continue to be entitled to receive milestone and tiered royalty payments on future net sales of ocadusertib and the companies' CNS penetrant program. Clinical Development Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R2891, a novel and selective dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). Enrollment in the dose escalation part of the study was completed in July. The company expects to share updated data from the study later this year and plans to initiate the dose expansion part of the study in the second half of this year. Rigel presented 4 posters at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and 3 posters at the European Hematology Association (EHA) 2025 Congress. Presentations included the final data from the GAVRETO (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, and supportive data for REZLIHDIA (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) relapsed or refractory (R/R) acute myeloid leukemia (AML). Key Publications A paper titled "Effectiveness of Olutasidenib versus Ivosidenib in Patients With Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm," was published in June by Catherine Lai, M.D., MPH, lead author and associate professor of Clinical Medicine, Division of Hematology-Oncology, Department of Medicine at University of Pennsylvania, in Leukemia & Lymphoma. A paper titled "Olutasidenib Alone or Combined with Azacitidine in Patients with Mutant IDH1 Myelodysplastic Syndrome," was published in July by Jorge E. Cortes, M.D., lead author and director, Georgia Cancer Center, Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer, in Blood Advances. This is the first full report of the safety and clinical activity of an mIDH1 inhibitor plus hypomethylating agent (HMA) combination in patients with treatment-naïve and R/R MDS. The paper showed olutasidenib, alone or in combination with azacitidine, induced a high rate of clinically meaningful complete remission and hematologic improvement responses with durable remission duration, accompanied by low rates of serious treatment-emergent-adverse events in patients with intermediate-, high- or very high-risk MDS harboring mIDH1. Second Quarter 2025 and Year-to-Date Financial Update For the second quarter ended June 30, 2025, total revenues were $101.7 million, consisting of $58.9 million in net product sales and $42.7 million in contract revenues from collaborations. Net product sales grew 76% compared to $33.5 million in the same period of 2024. TAVALISSE net product sales were $40.1 million, growth of 52% compared to $26.4 million in the same period of 2024. GAVRETO net product sales were $11.8 million compared to $1.9 million in the same period of 2024. GAVRETO became commercially available from Rigel in late June 2024. REZLIDHIA net product sales were $7.0 million, growth of 36% compared to $5.2 million in the same period of 2024. Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $2.0 million of revenue from Grifols S.A. (Grifols) related to delivery of drug supplies and earned royalties, $0.4 million of revenue from Kissei related to the delivery of drug supplies, and $0.2 million of revenue from Medison Pharma (Medison) related to delivery of drug supplies and earned royalties. Total costs and expenses were $40.6 million compared to $36.4 million for the same period of 2024. The increase in costs and expenses was mainly due to higher cost of product sales, increased research and development costs driven by the timing of clinical activities related to olutasidenib and R289, and higher personnel-related costs and stock-based compensation expense. Rigel reported net income of $59.6 million, or $3.33 basic and $3.28 diluted per share, compared to a net loss of $1.0 million, or $0.06 basic and diluted per share, for the same period of 2024. For the six months ended June 30, 2025, total revenues were $155.0 million, consisting of $102.5 million in net product sales and $52.5 million in contract revenues from collaborations. Net product sales grew 72% compared to $59.5 million in the same period of 2024. TAVALISSE net product sales were $68.5 million, growth of 44% compared to $47.5 million in the same period of 2024. GAVRETO net product sales were $20.8 million compared to $1.9 million in the same period of 2024. GAVRETO became commercially available from Rigel in late June 2024. REZLIDHIA net product sales were $13.1 million, growth of 31% compared to $10.0 million in the same period of 2024. Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $6.7 million of revenue from Grifols related to delivery of drug supplies and earned royalties, $5.1 million of revenue from Kissei related to a milestone payment and delivery of drug supplies and $0.6 million of revenue from Medison related to delivery of drug supplies and earned royalties. Total costs and expenses were $81.1 million compared to $72.9 million for the same period of 2024. The increase in costs and expenses was mainly due to higher cost of product sales, increased research and development costs driven by the timing of clinical activities related to olutasidenib and R289, and higher personnel-related costs. These increases were partially offset by decreased stock-based compensation expense primarily from performance-based stock awards. Rigel reported net income of $71.1 million, or $3.98 basic and $3.91 diluted per share, compared to a net loss of $9.3 million, or $0.53 basic and diluted per share, for the same period of 2024. Cash, cash equivalents and short-term investments as of June 30, 2025 was $108.4 million, compared to $77.3 million as of December 31, 2024. 2025 Outlook Rigel is updating its 2025 total revenue guidance to approximately $270 to $280 million, an increase from the previous range of approximately $200 to $210 million, which includes: Net product sales of approximately $210 to $220 million, an increase from the previous range of approximately $185 to $192 million. Contract revenues from collaborations of approximately $60 million, an increase from the previous range of approximately $15 to $18 million. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs. The above total revenues and contract revenues from collaborations are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly. Conference Call and Webcast with Slides Today at 4:30pm Eastern Time Rigel will hold a live conference call and webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). Participants can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). The conference call will also be webcast live and can be accessed from the Investor Relations section of the company's website at . The webcast will be archived and available for replay after the call via the Rigel website. About ITP In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP. About NSCLC It is estimated that over 226,000 adults in the U.S. will be diagnosed with lung cancer in 2025. Lung cancer is the leading cause of cancer death in the U.S, with non-small cell lung cancer (NSCLC) being the most common type accounting for 85-90% of all lung cancer diagnoses.2 RET fusions are implicated in approximately 1-2% of patients with NSCLC.3 About AML Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that there will be about 22,010 new cases in the United States, most in adults, in 2025.4 Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.5,6 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.7 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need. About TAVALISSE® TAVALISSE (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Please click here for Important Safety Information and Full Prescribing Information for TAVALISSE. About GAVRETO® GAVRETO is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).* *Thyroid indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Please click here for Important Safety Information and Full Prescribing Information for GAVRETO. About REZLIDHIA® REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Please click here for Important Safety Information and Full Prescribing Information, including Boxed WARNING, for REZLIDHIA. To report side effects of prescription drugs to the FDA, visit or call 1-800-FDA-1088 (800-332-1088). TAVALISSE, GAVRETO and REZLIDHIA are registered trademarks of Rigel Pharmaceuticals, Inc. About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit . R289 is an investigational compound not approved by the FDA. The American Cancer Society. Key Statistics for Lung Cancer. Revised January 16, 2025. Accessed March 31, 2025: Kato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679 The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML). Revised March 4, 2025. Accessed March 31, 2025: Patel, A, et al. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission. 2021 Sep 7;28(7):811-814. doi: Thol F, Ganser, A. Treatment of Relapsed Acute Myeloid Leukemia. Curr. Treat. Options on Oncol. (2020) 21: 66. doi: Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood (2015) 126 (3): 319-27. doi: Forward Looking Statements This press release contains forward-looking statements relating to, among other things, expected commercial and financial results, projected financial performance and outlook for 2025, expectations for growing our commercial business, potential investment in our pipeline, continued advancement and updated results of the dose escalation portion of our R289 study, continued ability for developing and commercializing TAVALISSE, GAVRETO, and REZLIDHIA domestically and in certain international markets, and expectations for Rigel's partnering and collaboration efforts. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements can be identified by words such as "anticipates", "plan", "outlook", "potential", "may", "look to", "expects", "will", "initial", "promising", and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib, olutasidenib and pralsetinib; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding fostamatinib, pralsetinib or olutasidenib; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that fostamatinib, pralsetinib or olutasidenib may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law. Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected] Media: David Rosen Argot Partners 646.461.6387 [email protected] SOURCE Rigel Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED